Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports.
Journal article

Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports.

  • Brockhaus L Department of Infectious Diseases, University Hospital Basel, Basel, Switzerland. lisa.brockhaus@unibas.ch.
  • Schmid Y Department of Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland.
  • Rast AC Allergy Unit, Department of Dermatology, University Hospital Basel, Basel, Switzerland.
  • Rätz Bravo AE Department of Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland.
  • Hofmeier KS Allergy Unit, Department of Dermatology, University Hospital Basel, Basel, Switzerland.
  • Leuppi-Taegtmeyer AB Department of Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland.
Show more…
  • 2019-02-14
Published in:
  • BMC pharmacology & toxicology. - 2019
English BACKGROUND
True hypersensitivity reactions to rifampicin are relatively rare, nonetheless severe manifestations mostly involving a single organ have been documented. We report a case of acute multi-organ failure occurring after a medication error with re-exposure to rifampicin.


CASE PRESENTATION
A 68-year old patient developed acute hypersensitivity pneumonitis, acute renal failure, acute liver failure and haemolytic anemia within hours after a second re-exposure to Rifampicin for the treatment of a hip prosthesis infection with Staphylococcus epidermidis. A recent rifampicin exposure 1 week earlier had resulted in a massive rise of CRP levels without organ manifestations. Nine years previously, the patient had developed a multi-organ hypersensitivity reaction 8 days after commencing treatment with rifampicin for pulmonary tuberculosis; and 23 years previously he had received rifampicin without problems. The organ-specific hypersensitivity reactions were largely reversible after withdrawal of rifampicin and treatment with steroids. A review of the literature and summary of WHO spontaneous safety reports is also given.


CONCLUSIONS
Re-exposure to rifampicin in sensitised individuals may cause acute severe hypersensitivity reactions. Due to its indications in the management of mycobacterial and implant-associated infections, rifampicin is a drug which might be given decades apart, which poses a risk that information about previous intolerance is lost.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/232386
Statistics

Document views: 24 File downloads: